论文部分内容阅读
目的观察左旋氨氯地平在降压过程中对高血压患者血清N端脑钠肽前体(NT-proB NP)水平的影响。方法将符合纳入标准的高血压患者100例随机分为试验组(50例)和对照组(50例),试验组予以左旋氨氯地平口服2.5 mg(qd),对照组予以缬沙坦胶囊口服80 mg(qd),用药3个月后监测2组治疗前后血清NT-proB NP水平。结果高血压患者血清NT-proB NP水平与阳性药对照组治疗前后比较,差异无统计学意义(P>0.05);服用左旋氨氯地平后,试验组血清NT-proB NP明显下降,差异有统计学意义(P<0.05)。结论左旋氨氯地平可降低高血压患者血清NT-proB NP水平,可改善临床预后。
Objective To investigate the effect of levamlodipine on the level of serum NT-proBNP in hypertensive patients during the antihypertensive treatment. Methods One hundred patients with hypertension were randomly divided into experimental group (50 cases) and control group (50 cases). The experimental group was given oral levamlodipine 2.5 mg (qd), while the control group was given valsartan capsule orally 80 mg (qd), three months after treatment, serum NT-proB NP levels were monitored before and after treatment in two groups. Results There was no significant difference in serum NT-proB NP levels between the two groups (P> 0.05). After treatment with L-amlodipine, the serum NT-proB NP level in the experimental group decreased significantly Significance (P <0.05). Conclusion Levamlodipine can reduce serum NT-proBNP level in patients with hypertension and improve clinical prognosis.